As the field moves towards precision therapies addressing the endothelial–metabolic axis, ALDH2 gene therapy in CVECs offers a promising, translationally relevant strategy to counteract HFpEF progression, particularly in metabolically compromised patients burdened by obesity and diabetes. Here, ALDH2 is linked to obesity due to melanocortin 4 receptor deficiency.